Trial · NCT03706365
Results by group33
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 33
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Radiographic Progression Free Survival (rPFS) | Abemaciclib | 21.96 | 95% Confidence Interval 19.33 to 27.48 | Months | |
| Radiographic Progression Free Survival (rPFS) | Placebo | 20.28 | 95% Confidence Interval 16.47 to 24.36 | Months | |
| Time to Prostate-Specific Antigen (PSA) Progression | Abemaciclib | 22.19 | 95% Confidence Interval 15.68 to 33.17 | Months | |
| Time to Prostate-Specific Antigen (PSA) Progression | Placebo | 16.60 | 95% Confidence Interval 12.03 to 20.28 | Months | |
| Radiographic Progression Free Survival (rPFS) Determined by Blinded Independent Central Review | Abemaciclib | 24.89 | 95% Confidence Interval 21.96 to NA | Months | |
| Radiographic Progression Free Survival (rPFS) Determined by Blinded Independent Central Review | Placebo | 22.88 | 95% Confidence Interval 19.36 to 31.50 | Months | |
| Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR) | Abemaciclib | 45.2 | 95% Confidence Interval 34.6 to 55.9 | percentage of participants | |
| Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR) | Placebo | 54.8 | 95% Confidence Interval 43.4 to 66.2 | percentage of participants | |
| Duration of Response (DOR) | Abemaciclib | 21.27 | 95% Confidence Interval 16.60 to NA | Months | |
| Duration of Response (DOR) | Placebo | 15.68 | 95% Confidence Interval 11.87 to 39.35 | Months | |
| Overall Survival (OS) | Abemaciclib | 38.01 | 95% Confidence Interval 30.58 to 46.65 | Months | |
| Overall Survival (OS) | Placebo | 33.21 | 95% Confidence Interval 29.52 to NA | Months | |
| Time to Symptomatic Progression | Abemaciclib | 51.39 | 95% Confidence Interval 27.98 to NA | Months | |
| Time to Symptomatic Progression | Placebo | 35.74 | 95% Confidence Interval 28.44 to NA | Months | |
| Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib | Abemaciclib | C1 D1 | 4.79 | Geometric Coefficient of Variation 157 | nanogram per milliliter (ng/mL) |
| Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib | Abemaciclib | C1 D15 | 289 | Geometric Coefficient of Variation 58.7 | nanogram per milliliter (ng/mL) |
| Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib | Abemaciclib | C2 D1 | 253 | Geometric Coefficient of Variation 65.7 | nanogram per milliliter (ng/mL) |
| Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib | Abemaciclib | C2 D15 | 252 | Geometric Coefficient of Variation 68.4 | nanogram per milliliter (ng/mL) |
| Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib | Abemaciclib | C3 D1 | 270 | Geometric Coefficient of Variation 54.5 | nanogram per milliliter (ng/mL) |
| PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN2839567 | Abemaciclib | C1 D1 | 2.90 | Geometric Coefficient of Variation 87.4 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03706365/results